( OTC-BB:DMPI )

News from delmar pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Oct 19, 2015, 07:00 ET DelMar Pharmaceuticals Presents Positive Preclinical Data on VAL-083 as a Promising Treatment for Ovarian Cancer

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...


Oct 14, 2015, 08:00 ET DelMar Pharmaceuticals to Present at the 14th Annual BIO Investor Forum

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...


Oct 13, 2015, 08:00 ET DelMar Pharmaceuticals Launches Digital Corporate Communication Channels

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...


Sep 29, 2015, 07:00 ET DelMar Pharmaceuticals to Present Data on the Promising Potential of VAL-083 in the Treatment of Pediatric Brain Tumors

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...


Sep 28, 2015, 08:21 ET DelMar Pharmaceuticals to Present an Interactive Live Webcast at VirtualInvestorConferences.com on October 1, 2015

- Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual event on Oct. 1 at 10:00 a.m....


Sep 10, 2015, 07:05 ET DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme at GBM2015

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...


Sep 08, 2015, 11:30 ET DelMar Pharmaceuticals Presents Clinical Protocol for Advancement of VAL-083 into Phase IV Studies as a Treatment for Non-Small Cell Lung Cancer

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...


Sep 04, 2015, 07:30 ET DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...


Sep 02, 2015, 08:05 ET DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...


Aug 27, 2015, 08:05 ET DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...


Aug 25, 2015, 07:35 ET DelMar Pharmaceuticals to Present at the 17th Annual Rodman & Renshaw Global Investment Conference on September 9, 2015

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...


Aug 24, 2015, 08:05 ET DelMar Pharmaceuticals to Present VAL-083 Lung Cancer Clinical Strategy at the 16th World Conference on Lung Cancer

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...


Aug 20, 2015, 07:35 ET DelMar Pharmaceuticals Completes $2.6 Million Registered Direct Offering

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing...


Aug 17, 2015, 08:05 ET DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from NRC-IRAP to Support Expanded Research Program with Lead Product Candidate VAL-083

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing...


Jul 27, 2015, 09:35 ET DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing...


Jul 20, 2015, 07:35 ET DelMar Pharmaceuticals Expands GBM Clinical Trial with Fifth Clinical Trial Site Added in Denver, Colorado

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and...


Jul 09, 2015, 07:35 ET DelMar Pharmaceuticals to Present Updated Phase I/II Clinical Data on VAL-083 in the Treatment of Refractory Glioblastoma Multiforme at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing...


Jun 15, 2015, 08:05 ET DelMar Pharmaceuticals Invited to Present at The World NSCLC Summit on June 23-24, 2015

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing...


Jun 10, 2015, 08:35 ET DelMar Pharmaceuticals to Present at the BIO International Convention on June 17, 2015

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing...


Jun 01, 2015, 14:29 ET DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and...